Company: ERAS
Filing Date: 2025-08-12
Form Type: S-3
Source: 0001193125-25-179038
Chunk: 45

Company: Erasca, Inc.
Filing Date: 2025-08-12
Form: S-3
Chunk 45
---

antibody). We believe our world-class team’s capabilities and experience, further guided by our scientific advisory board, which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold
mission of erasing cancer.

We were incorporated under the laws of the state of Delaware on July 2, 2018. Our principal executive offices are located
at 3115 Merryfield Row, Suite 300, San Diego, California 92121, and our telephone number is (858) 465-6511.

S-4

THE OFFERING

| Common stock offered by us | Shares of our common stock having an aggregate offering price of up to $200 million. |

| Common stock outstanding immediately following the offering | 426,507,281 shares, assuming sales of 142,857,142 shares in this offering at an assumed offering price of $1.40 per share, which was the last reported sale price of our common stock on the Nasdaq Global Select Market on August 8, 2025. The 
 actual number of shares issued will vary depending on how many shares of our common stock we choose to sell and the prices at which such sales occur.                                                                                           |

| Plan of Distribution | “At the market offering” that may be made from time to time on the Nasdaq Global Select Market or other market for our common stock in the United States through our sales agent, Jefferies. See the section entitled “Plan of 
 Distribution” in this prospectus.                                                                                                                                                                                              |

| Use of Proceeds | We intend to use the net proceeds of this offering, together with our existing cash, cash equivalents and marketable securities, to fund the research and development of our product candidates and other development programs and for working 
 capital and general corporate purposes. We may also use a portion of the remaining net proceeds and our existing cash, cash equivalents and marketable securities, to in-license, acquire, or invest in                                        
 complementary businesses, technologies, products or assets; however, we have no current commitments or obligations to do so. See “Use of Proceeds.”                                                                                            |

| Risk Factors | See the section titled “Risk Factors” on page S-6 in this prospectus and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors you should carefully consider before 
 deciding to invest in shares of our common stock.                                                                                                                                                                                       |

| Nasdaq Global Select Market symbol | “ERAS” |

The number of